Celea Therapeutics, a PureTech Founded Entity, has appointed former KalVista Pharmaceuticals chief medical officer Paul Audhya as Chief Medical Officer. He will oversee the Phase 3 SURPASS-IPF trial of deupirfenidone in idiopathic pulmonary fibrosis.
What was announced
PureTech Health (LSE:PRTC) plc said on 29 October 2026 that Celea Therapeutics, Inc., a Boston-based company founded by PureTech and later spun off from it, has appointed Paul Audhya, MD, MBA, as Chief Medical Officer. He will be responsible for clinical development and medical strategy, including the ongoing Phase 3 SURPASS-IPF trial.
Dr Audhya brings nearly three decades of experience in clinical development and global medical affairs. He was most recently Chief Medical Officer of KalVista Pharmaceuticals, where he led global clinical development strategy and regulatory submissions in major international markets. He previously held senior leadership roles at Arena Pharmaceuticals, Vertex Pharmaceuticals, Hospira and Reata Pharmaceuticals, and roles of increasing responsibility at Abbott Laboratories, Amgen, Bristol-Myers Squibb and Janssen Pharmaceuticals. According to the announcement, he has guided programmes from development through to commercialisation across several therapeutic areas, including rare diseases.
The programme
Celea is a clinical-stage biopharmaceutical company focused on therapies for serious respiratory diseases with significant unmet need. Its lead candidate is deupirfenidone, an investigational oral antifibrotic that the company describes as a next-generation treatment built on the established antifibrotic foundation of pirfenidone.
Deupirfenidone is being studied in idiopathic pulmonary fibrosis, or IPF, a progressive and fatal lung disease, in the Phase 3 SURPASS-IPF trial. The company said it aims in future to evaluate the drug in other progressive fibrotic interstitial lung diseases, although these uses have not yet been studied.
Celea closed a $180 million financing in July 2026, according to the release. The announcement does not state PureTech's ownership stake in Celea, and it gives no timelines for trial enrolment, data readouts or regulatory filings.
Leadership team
Dr Audhya joins a leadership team headed by Chief Executive Sven Dethlefs, PhD. Other members are Chief Financial Officer Vishwas Setia, formerly CFO of MapLight Therapeutics, where he led its Series D financing and initial public offering after about a decade in healthcare investment banking at BofA Securities; Chief Operating Officer Ronen Tamir, who has held leadership roles at Pfizer, Teva, GE Healthcare, Rosetta Genomics, Novartis and EMD Serono; and General Counsel David M. Stark, formerly Chief Legal Officer of Teva, where he led its global legal organisation for nearly a decade.
Dr Dethlefs said the appointment was "an important step in building out the leadership team" for Celea's next phase of growth. Dr Audhya said the company aims to move beyond the trade-off between efficacy and tolerability in IPF treatment, and described the start of Phase 3 as "a transformative milestone".
Why it matters for PureTech
PureTech describes itself as a hub-and-spoke biotherapeutics company using a capital-efficient research and development model. It says its approach has produced dozens of therapeutic candidates, three of which have received approval from the US Food and Drug Administration. Celea is one of the founded entities through which PureTech progresses its programmes, and its value to PureTech shareholders depends in part on how deupirfenidone performs in late-stage development. Because the announcement does not disclose PureTech's percentage holding, the scale of PureTech's economic exposure to Celea cannot be calculated from this release.
What to watch next
The main milestone for Celea is the progress of the SURPASS-IPF Phase 3 trial, which Dr Audhya will now lead from a clinical perspective. Investors may look for future disclosures on enrolment, the timing of top-line data and any plans to extend deupirfenidone into other fibrotic lung diseases. The announcement contained no financial guidance for either Celea or PureTech, and no specific dates for these milestones were given. Updates on PureTech's own stake in Celea, and on how the July financing affected it, would also help clarify the parent's exposure to the programme.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...